Additional file 1 of Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients

Additional file 1: Table S1 & S2; Fig. S1-S6. Table S1: Additional testing selection criteria; Table S2: Antibodies for IHC-IHC; Fig. S1_1 and S1_2: ADC-IHC evaluation by H Score; Fig. S2: Sample information; Fig. S3: Recommendations based on entity + evidence levels; Fig. S4: Recommendations based on genetic alterations; Fig. S5: TMB distribution by entity; Fig. S6: Survival analyses.